Ãæ³²´ëÇб³º´¿ø Çѱ¹À¯¹æ¾ÏÇÐȸ 2018 Ãß°èÇмú´ëȸ : 2018-10-20±³À°ÀÏÀÚ : 2018-10-20
±³À°Àå¼Ò : Ãæ³²´ëÇб³º´¿ø ÀçÈ°.°üÀý¿°¼¾ÅÍ 3Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
2018 Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060
À̸ÞÀÏ :
kbcs@kbcs.or.kr ±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
Ãæû³²µµ±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 10:35~11:00 Introduction of Immunology to understand immunotherapy ±èÀº±Ô(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 11:00~11:25 Recent updates in immunotherapy in breast cancer patients ¹ÎÁØ¿ø(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 11:25~11:50 Immunotherapy to overcome the resistance to anti-Her2 therapy ¼±¿ì¿µ(°¡Å縯ÀÇ´ë)
½Ä»ç 10¿ù 20ÀÏ 11:50~13:00 Lunch ()
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 13:00~13:25 Personalized neoadjuvant strategy in Luminal A breast cancer TO increase BCS rate[PLATO Study] ÇÑ¿ø½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 13:25~13:50 Clinical Study for the Efficacy of GnRH agonists in Breast Cancer Patients À¯Á¾ÇÑ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 13:50~14:15 ¿ì¶ó³ª¶óÀÇ °øÀÍÀû Àӻ󿬱¸ Áö¿ø ±è¼®Çö(NECA)
ÈÞ½Ä 10¿ù 20ÀÏ 14:15~14:30 Break ()
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 14:30~14:55 Invasive lobular carcinoma: different apporaches from ductal carcinoma? ÀÌÁø¼±(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 14:55~15:20 Pathophysiology and the optimal managements of Inflammatory breast cancer ÀÌÀ±ÁÖ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 15:20~15:45 Recent advances in male breast cancer ±Ç¼º¿í(°Ç¾çÀÇ´ë)
ÈÞ½Ä 10¿ù 20ÀÏ 15:45~16:00 Break ()
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 16:00~16:25 Proper monitoring and management for the treatment related cardiotoxicity À±ÇöÁ¶(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 16:25~16:50 Acute and chronic complications from Radiation treatment ±ÇÁøÀÌ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 20ÀÏ ´ë°´ç 16:50~17:15 Myth or fact? Vitamin therapy / Hyperthermia ¹ÚÇü¼®(¿¬¼¼ÀÇ´ë)